Real world efficacy and durability of faricimab in patients with neovascular AMD (nAMD) who had sub-optimal response to prior anti-VEGF therapy

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

The Lancet · 2022 · 686 citations · Full text

Medicine, Ophthalmology, Vision Science +11

The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study – 6 month results

Arshad M. Khanani, Aamir Aziz, Hannah Khan et al. · Eye · 2023 · 167 citations · Full text

Medicine, Ophthalmology, Pharmacotherapy +8

Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013

Ana Quartilho, Philippa Simkiss, Antra Zekite et al. · Eye · 2016 · 162 citations · Full text

Medicine, Ophthalmology, Ocular Disease +13

Oncolytic adenovirus expressing interleukin-18 improves antitumor activity of dacarbazine for malignant melanoma

Chunhua Yang, Hang Cao, Ning Liu et al. · Drug Design Development and Therapy · 2016 · 117 citations · Full text

Medicine, Oncology, Pharmacology +15

Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration

Ella H. Leung, Daniel J. Oh, Shannon E. Alderson et al. · Clinical ophthalmology · 2023 · 91 citations · Full text

Medicine, Ophthalmology, Surgery +14